Inozyme Pharma to Present at Upcoming Investor Conferences
May 03, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
April 14, 2022 08:16 ET
|
Inozyme Pharma Inc.
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
April 12, 2022 07:30 ET
|
Inozyme Pharma Inc.
- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of...
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
April 04, 2022 07:30 ET
|
Inozyme Pharma Inc.
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) – - PPi increased in all three patients to levels...
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights
March 15, 2022 17:24 ET
|
Inozyme Pharma Inc.
– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway – – Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficiency in the second quarter of 2022 – –...
Inozyme Pharma Strengthens Management Team with Two Executive Appointments
March 08, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference
March 01, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
November 15, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...